Author

Sambuddha Basu

Spark Therapeutics (United States)ORCID 0000-0002-1281-1543Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:ChIP-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

Alexandra J Gilsrud· 1 shared Apeksha Khatiwada· 1 shared Brittany Wicks· 1 shared Daniel Cohen· 1 shared Derek P. NarendraiD· 1 shared Elizabeth A. Ramsburg· 1 shared Eric Wildon KostukiD· 1 shared Evan R. AdleriD· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alexandra J Gilsrud

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NeurosciencebioRxivPreprintJul 13, 2026

Restoring Parkin Function: An AAV Gene Therapy Approach for Early-Onset Parkinson's Disease

Sambuddha Basu, Tyler G. Demarest, Nicholas J. Gattone…·Elizabeth A. Ramsburg

This paper investigates AAV-mediated PRKN gene replacement in Parkin-deficient models to restore mitophagy and demonstrate a feasible gene therapy approach for early-onset Parkinson's disease.

DOI 10.64898/2026.07.09.737487

humanmouse

𝕏 PostBluesky

NeuroscienceEMBO Molecular MedicinePeer-reviewedJan 11, 2021

Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease

Subhrangshu Guhathakurta, Jin-Il Kim, Levi Adams…·Yoon‐Seong Kim

This study shows that reducing H3K4me3 at the SNCA promoter using CRISPR/dCas9-JARID1A lowers α-synuclein in Parkinson's disease models.

92 citationstop 2%

humanChIP-seq

𝕏 PostBluesky